CI-990 (PD-131112) - A NEW QUINOLONE PRODRUG

In vitro susceptibility of 1021 strains of recent clinical isolates wa s determined against the new fluoroquionolone CI-990 (PD 131112) and c ompared with CI-960, ciprofloxacin, fleroxacin, lomefloxacin, norfloxa cin, pefloxacin. sparfloxacin. and temafloxacin. The minimum inhibitor y concentrations (MIC) of CI-990 in mg/L required for >90% isolates we re 0.03-0.5 for members of Enterobacteriaceae. 0.12-2.0 for Pseudomona s aeruginosa, 0.03-1.0 for Aeromonas hydrophila, 1.0-2.0 for Acinetoba cter calcoaceticus, 0.5-2.0 for Brucella melitensis, 0.06-1.0 for stap hylococci, and 1.0-2.0 for enterococci. Its antibacterial activity was comparable or superior to other fluoroquinolones tested against most gram-negative and gram-positive bacteria, including enterococci.